Ardian was formed in 2004 to develop treatments for hypertension and heart failure. Developed Symplicity catheter renal denervation system. Following successful completion of a randomized controlled study in Europe, Ardian was acquired for $850 million by Medtronic in 2011. Renal denervation is now being commercialized by Medtronic and others.

Cabochon Aesthetics, formed in 2005, developed Cellfina, a minimally-invasive, FDA cleared treatment for improving the appearance of cellulite. Acquired by Ulthera/Merz, Inc. in 2014, Cellfina is in use worldwide.

Founded in 2003, Cierra developed an implant-free patent foramen ovale closure treatment to reduce the recurrence of ischemic stroke and migraine headache. Cierra was acquired by Terumo Corporation.

Formed in 1999 to address unmet needs in stroke and neurovascular therapy. Developed the Merci thrombectomy catheter for ischemic stroke. Acquired by Stryker in 2011 for $135 million. Acute thrombectomy is now standard-of-care for stroke, and has saved tens of thousands of lives.

Cotera was formed in 2011 to address pain and damage associated with osteoarthritis of the knee and other joints. Developed the Latella implant for medial knee pain due to osteoarthritis. The Latella technology was licensed by Moximed in 2018.

Formed in 2000 to address unmet needs in respiratory disease. Developed the Zephyr valve for endobronchial lung volume reduction to treat severe emphysema. Acquired by Pulmonx in 2009. The Zephyr valve is currently the leading device treatment for severe emphysema in the United States.

Formed in 1999 to address unmet needs in mitral valve disease. Developed the MitraClip for transcather mitral valve repair. Acquired by Abbott Labs in 2009 for up to $410 million. It has treated over 100,000 patients. Now a billion-dollar annual business for Abbott.

First to File was formed in 2000 to revolutionize the intellectual property process. Acquired by MarkMonitor in 2002 to form an integrated suite of intellectual property tools. Now part of CPA Global.

ForSight Labs, an ophthalmic company incubator, was formed in 2005 in partnership with Dr. Eugene de Juan, Jr. and K. Angela Macfarlane. Six companies were formed to develop treatments for glaucoma, retinal diseases, conjunctivitis and dry eye. Four of these companies have been acquired to date, by Alcon, Allergan, Roche and QLT.

ForSight Newco II (Vision2) was founded in 2006 to develop a proprietary ocular punctal plug drug delivery system (PPDS) for various opthalmic conditions. Vision2 was acquired by QLT in 2007. In 2013, the PPDS technology was sold to Mati Therapeutics, which continues to develop the technology.

Foundry Newco XI was started to develop tools and techniques to make arthroscopic repair of the hip joint safer and easier. These tools were acquired by Pivot Medical/Stryker.

Miramar Labs, founded in 2006, developed the miraDry System to treating excessive sweating, odor, and hair removal. Miramar Labs was acquired in 2017 by Sientra, which sold the miraDry business to 1315 Capital, a private equity firm, in 2021. The MiraDry system is in use worldwide.

Satiety was formed in 2001 to develop minimally invasive devices to treat obesity and certain other gastrointestinal conditions. Satiety completed a successful randomized trial demonstrating significant excess weight loss. In 2011, the technology was sold to a major medical device company.

Transcend Medical was formed in 2005 out of the ForSight Labs incubator. Transcend developed the CyPass Micro-Stent for minimally invasive glaucoma surgery. Acquired by Novartis Alcon in 2016

Twelve was founded in 2009 to develop new treatments for mitral valve disease. Developed the Intrepid transcatheter mitral valve replacement system. Acquired by Medtronic in 2015 for $458 million. In clinical trials worldwide.

Founded in 2002, Xtent developed drug-eluting stent systems of customizable length for the treatment of coronary artery disease. Xtent had a successful IPO in 2007. In 2009, the technology was sold to JW Medical, Inc.